Inogen INGN
Inogen's growth is built on a reseller network that lies to elderly customers about Medicare coverage to force cash sales — competition and oversight will collapse margins to a $46 stock.
Thesis
Citron argues Inogen's portable oxygen concentrator growth depends on a deceptive sales scheme: only sub-10% of revenue comes from Medicare even though the average customer is 75+ and Medicare covers 80% of POC cost. Inogen's largest 'authorized reseller,' 1st Class Medical, is fronted by Caleb Umstead but secretly run by Gary Luckner, recently sentenced to 90 months for online fraud. Citron documents live-chat transcripts where reps tell seniors Medicare doesn't cover POCs, contradicting Inogen's own 10-K disclosure of Medicare codes E1390/E1392. Combined with new CMS competitive-bidding rules letting any DME serve Medicare patients and ResMed's R&D push, Inogen's cash-conversion model is breaking. If Medicare share rose to 40%, revenue would fall ~20% and EPS ~80%; Citron sets a $46 price target.
SCQA
Inogen is the dominant pure-play in portable oxygen concentrators, sold to a customer base averaging 75+ through both direct-to-consumer reps and a network of 'authorized internet resellers' led by 1st Class Medical.
Less than 10% of revenue comes from Medicare despite 80% coverage being available; Citron documents that resellers and Inogen reps systematically lie about Medicare coverage to push cash sales, and the top reseller is secretly controlled by a convicted internet-fraud felon, Gary Luckner.
Sell or short the stock; Citron has also referred the report to the DOJ, FTC, CFPB Office for Older Americans, and elder-protection groups, anticipating regulatory action and accelerated competitive pressure from CMS bidding rule changes.
If Medicare's share of POC units rose from ~10% to a more normal ~40%, revenue would fall ~20% and EPS ~80%, with multiple compression; Citron's resulting target is $46 per share.
The three reasons
- 1
Less than 10% of Inogen's revenue comes from Medicare despite serving 75+ population
- 2
Top reseller 1st Class Medical is secretly run by a convicted felon (Gary Luckner)
- 3
Mix shift to Medicare would cut revenue ~20% and EPS ~80%, crushing the multiple
Primary demands
- Investors should sell/short Inogen on expectation of de-rating to $46
- Regulators (DOJ, FTC, CFPB Office for Older Americans) should investigate Inogen's reseller network for elder abuse
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- Muddy Waters' 27-page TAM short report on Inogen (Feb 2019, Carson Block)
Notable slides (6)
Notes
Classic Citron 'moral outrage' short report — frames a financial short thesis as elder-abuse exposé to amplify regulatory risk. Stacks on top of a Muddy Waters TAM report released the prior week, explicitly positioning itself as the 'dirtier secrets' follow-up. Mocks WinterGreen Research (the source of Inogen's TAM) by showing a photo of its modest house headquarters. Uses live-chat transcripts and Glassdoor/Indeed/BBB review snippets as primary 'evidence.' Author is the firm (Citron Research / Andrew Left implied but not signed); no individual signature on cover or close. Date inferred from filename '2019-02' and reference to Muddy Waters report dated 2019-02-08; precise day not on cover so set to 2019-02-15 as a mid-month estimate.